Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease
Objectives: Levodopa-carbidopa intestinal gel (LCIG) was developed to reduce motor complications in Parkinson’s disease (PD) caused by pulsatile levodopa plasma concentrations following oral levodopa administration. Dyskinesia and ‘wearing off’ symptoms can vary between Asian and Caucasian patients...
Main Authors: | Miho Murata, Masahito Mihara, Kazuko Hasegawa, Beomseok Jeon, Chon-Haw Tsai, Noriko Nishikawa, Tomoko Oeda, Masayuki Yokoyama, Weining Z. Robieson, Krai Chatamra, Maurizio F. Facheris, Janet Benesh |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2018-02-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756286418759315 |
Similar Items
-
Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa
by: Cindy Zadikoff, et al.
Published: (2020-01-01) -
Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
by: Werner Poewe, et al.
Published: (2020-06-01) -
A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies
by: James T. Boyd, et al.
Published: (2020-01-01) -
Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease
by: Masahiro Nomoto, et al.
Published: (2018-12-01) -
Membranous nephropathy associated with the use of levodopa-carbidopa combination
by: V Chaitanya, et al.
Published: (2015-01-01)